LpD3.5 Intervention Study in Older Adults- LISA-I Trial
University of South Florida · NCT07794956
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 60+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 15
- US sites recruiting
- 1
- Study start
- March 3, 2026
- Record last updated
- August 31, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This randomized placebo-controlled clinical study, called the LpD3.5 Intervention Study in Older Adults (LISA), aims to evaluate whether a heat-inactivated postbiotic of human origin (LpD3.5) can serve as a non-pharmacological intervention to reduce gut permeability and inflammation in older adults with mild cognitive impairment (MCI). The study will assess the effects of LpD3.5 supplementation on markers associated with gut health, inflammation, microbiome composition, and cognitive function.
Participants aged 60 years or older with clinically diagnosed MCI will receive either LpD3.5 capsules or placebo capsules for 60 days, followed by a 30-day follow-up period. Biological samples and clinical assessments will be collected to evaluate changes in gut permeability, inflammatory markers, microbiome characteristics, and cognitive outcomes. The findings from this study may provide insight into the potential role of postbiotics as a dietary intervention to improve gut health and related outcomes in older adults with MCI.
Being studied: LpD3.5; Placebo
Conditions: Mild Cognitive Impairment (MCI); Cognition; Brain Aging; Microbiome Dysbiosis; Leaky Gut Syndrome; Gut Inflammation; Inflammaging
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Age 60 years and above; (ii) physician based clinically diagnosed MCI and the Montreal Cognitive Assessment (MoCA) score between 18 and 25; iii) LBP ≥ 30 μg/mL in plasma, and (iv) willing to sign informed consent, take intervention regimen, follow study team guidelines and donate sam-ples, as instructed by the study team; and (iv) live with a partner or care giver
Study partners in this study must meet the following inclusion criteria:
- Be 60 years or older
- Willingness to participate in the study and provide consent
- Ability to have regular contact with the participant(s)
- Be knowledgeable about the participant's health, memory, and daily activities
- Communicate effectively in English
Exclusion Criteria
Brain and gut related surgery within the past 5 years that affected cognitive function: This information will be collected during the initial telephonic screening through an eligibility checklist. (ii) diagnosis of inflammatory bowel disease, ulcerative colitis, Crohn's disease, acid reflux, gastroesophageal reflux disease, Clostridium difficile infection, or any other gastrointestinal disease that might significantly change the microbiome, gut permeability, and inflammation: Participants will be asked about these diagnoses during the telephonic screening, and responses will be documented : Participants will be asked about these diagnoses during the telephonic screening, and responses will be documented. (iii) history of fecal microbiota transplantation and small intestinal bacterial growth: These conditions will also be screened via the initial eligibility questionnaire ad-ministered during the pre-screening phone interview. (iv) history of cancer or cancer treatment in past 5 years: Participants will be asked to report any history of cancer or treatment during the tele-phonic screening (v) nausea, vomiting, food poisoning, constipation, or diarrhea and/or antibiotic use in the past 30 days; These symptoms will be captured via a brief symptom checklist completed at the time of recruitment as well as on-site at the initial study visit. (vi) heavy consumption of pro-biotics, yogurt, or other fermented food (>4 servings per day): Questionnaire on probiotic yogurt, or other fermented food will be administered during the initial screening by telephonic talk as well as on-site visit to capture this information.(vii) critical or terminal illnesses; (viii) having neurological disorders like epilepsy, Parkinson's disease and Amyotrophic lateral sclerosis: These conditions will be assessed via direct questioning during the telephonic pre-screening interview (ix) pregnant or prisoner: Pregnancy status will be determined via verbal confirmation during screening and documented in the eligibility checklist. (x) unable to eat the test product according to the regulations; (xi) participating in other clinical trial; (xii) any diagnosis or condition that renders the subject ineligible at the discretion of the PI and/or the study team.
Recruiting US locations
Department of Neurosurgery and Brain and Spine and Faculty of USF Center for Microbiome Re-search, Microbiomes Institute
Tampa, FL 33612
Site contact: Hariom Yadav, PhD · 8139748222 · hyadav@usf.edu
Study contacts (from the official record)
- Hariom Yadav, PhD · 8139748222 · hyadav@usf.edu
- Shalini Jain, PhD · +1 8139746281 · jains10@usf.edu
Similar studies in Florida
All neurology studies in Florida →- RecruitingHealthy volunteersPhase 1
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
Eli Lilly and Company
- Location
- Daytona Beach, FL
- Eligibility basics
- Ages 18–85
- RecruitingHealthy volunteersPhase 1
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
Prevail Therapeutics
- Location
- Naples, FL + 1 other US site
- Eligibility basics
- Ages 30–80
- RecruitingHealthy volunteersPhase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Eli Lilly and Company
- Location
- Naples, FL + 7 other US sites
- Eligibility basics
- Ages 30–85
- RecruitingHealthy volunteersPhase 1
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
Eli Lilly and Company
- Location
- Daytona Beach, FL
- Eligibility basics
- Ages 18–85